Cited by 314Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

Monoclonal antibodies that target pathological assemblies of Aβ

Lambert, Mary P., Velasco, Pauline T., Chang, Lei, Viola, Kirsten L., Fernandez, Sara, Lacor, Pascale N., Khuon, Daliya, Gong, Yuesong +5 more·2007·Journal of Neurochemistry

Abstract

Amyloid beta (Abeta) immunotherapy for Alzheimer's disease has shown initial success in mouse models of Alzheimer's disease and in human patients. However, because of meningoencephalitis in clinical trials of active vaccination, approaches using therapeutic antibodies may be preferred. As a novel antigen to generate monoclonal antibodies, the current study has used Abeta oligomers (amyloid beta-derived diffusible ligands, ADDLs), pathological assemblies known to accumulate in Alzheimer's disease brain. Clones were selected for the ability to discriminate Alzheimer's disease from control brains in extracts and tissue sections. These antibodies recognized Abeta oligomers and fibrils but not the physiologically prevalent Abeta monomer. Discrimination derived from an epitope found in assemblies of Abeta1-28 and ADDLs but not in other sequences, including Abeta1-40. Immunoneutralization experiments showed that toxicity and attachment of ADDLs to synapses in culture could be prevented. ADDL-induced reactive oxygen species (ROS) generation was also inhibited, establishing this response to be oligomer-dependent. Inhibition occurred whether ADDLs were prepared in vitro or obtained from Alzheimer's disease brain. As conformationally sensitive monoclonal antibodies that selectively immunoneutralize binding and function of pathological Abeta assemblies, these antibodies provide tools by which pathological Abeta assemblies from Alzheimer's disease brain might be isolated and evaluated, as…

Integrity signals

Registry

Crossref · 10.1111/j.1471-4159.2006.04157.x

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lambert, M. P., Velasco, P. T., Chang, L., Viola, K. L., Fernandez, S., Lacor, P. N., Khuon, D., Gong, Y., Bigio, E. H., Shaw, P., De Felice, F. G., Krafft, G. A., & Klein, W. L.
Affiliations
Northwestern University (US)
Corresponding author
Klein, William L.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2006-08-21
Volume
100
Issue
1
Pages
23-35
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W2078212921
Cited by
314
References
17
Citations by year
2026: 1 · 2025: 3 · 2024: 1 · 2023: 13 · 2022: 14 · 2021: 14 · 2020: 12 · 2019: 14 · 2018: 15 · 2017: 12 · 2016: 14 · 2015: 20 · 2014: 25 · 2013: 14 · 2012: 28
FWCI
13.04
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Neurochemistry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Southern California
  • Northwestern University
  • National Institutes of Health
  • National Institute on Aging (R01 AG11385, AG 22547, P30AG13854, R01AG022547, R01AG011385, R01-AG18877, P30AG013854, R01AG018877)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
amyloid-beta oligomers, monoclonal antibodies, Alzheimer's disease, immunoneutralization, reactive oxygen species, therapeutic antibodies, amyloid fibrils
MeSH terms
Adducins, Alzheimer Disease, Animals, Antibodies, Monoclonal, Antibody Specificity, Epitopes, Brain, Calmodulin-Binding Proteins, Cells, Cultured, Dose-Response Relationship, Drug, Glial Fibrillary Acidic Protein, Humans, Immunohistochemistry, Neurons, Peptide Fragments, Protein Binding, Rabbits, Tetrazolium Salts, Thiazoles, Immunoblotting, Amyloid beta-Peptides, Reactive Oxygen Species, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review